微胃泌素类似物的临床前评估及[68Ga]Ga-DOTA-CCK-66在2例甲状腺髓样癌患者中的概念验证PET/CT
针对靶向胆囊收缩素-2受体(CCK-2R)的微胃泌素类似物稳定性问题,本研究开发了DOTA-CCK-66和DOTA-CCK-66.2,在体外和AR42J荷瘤小鼠中评估其CCK-2R亲和力、体内稳定性和生物分布,并在2例甲状腺髓样癌(MTC)患者中完成[68Ga]Ga-DOTA-CCK-66 PET/CT概念验证,确认多发转移灶。
要点
- DOTA-CCK-66对CCK-2R亲和力高(IC50 3.6-6.0 nM),[177Lu]Lu-DOTA-CCK-66小鼠尿中完整肽比例高于[177Lu]Lu-DOTA-MGS5。
- [67Ga]Ga-DOTA-CCK-66在AR42J荷瘤小鼠1小时肿瘤摄取高(19.4 ± 3.5 %ID/g),血、肝、胰低。
- 2例MTC患者[68Ga]Ga-DOTA-CCK-66 PET/CT(注射后120分钟)确认多发转移灶,生物分布良好。
核心结论
- 因[67Ga]Ga-DOTA-CCK-66和[177Lu]Lu-DOTA-CCK-66体内稳定性高且临床前整体性能良好,完成了[68Ga]Ga-DOTA-CCK-66的概念验证临床研究。
- 因可识别多个病灶且观察到良好生物分布,作者认为有必要进一步开展[68Ga]Ga-和[177Lu]Lu-DOTA-CCK-66的患者研究。
研究设计与样本
- 临床前研究:对DOTA-CCK-66、DOTA-CCK-66.2和DOTA-MGS5进行64Cu、67Ga、177Lu标记,在AR42J细胞检测CCK-2R亲和力,在CB17-SCID小鼠评估体内稳定性及AR42J荷瘤小鼠生物分布。
- 临床转化:2例MTC患者注射[68Ga]Ga-DOTA-CCK-66后120分钟行全身PET/CT。
主要发现
- 无论使用铜、镓或镥,CCK-2R亲和力均高(半抑制浓度3.6-6.0 nM),亲脂性良好。
- 小鼠尿中完整肽比例:[177Lu]Lu-DOTA-CCK-66为23.7% ± 9.2%,[177Lu]Lu-DOTA-MGS5为77.8% ± 2.3%。
- 两种177Lu标记类似物的总体肿瘤/背景比值相似。
- [67Ga]Ga-DOTA-CCK-66注射后1小时肿瘤摄取为19.4 ± 3.5 %ID/g,血0.61 ± 0.07、肝0.31 ± 0.02、胰0.23 ± 0.07、胃1.81 ± 0.19、肾2.51 ± 0.49 %ID/g。
- 2例MTC患者[68Ga]Ga-DOTA-CCK-66 PET/CT确认多发转移灶。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Because of the need for radiolabeled theranostics for the detection and treatment of medullary thyroid cancer (MTC), and the yet unresolved stability issues of minigastrin analogs targeting the cholecystokinin-2 receptor (CCK-2R), our aim was to address in vivo stability, our motivation being to develop and evaluate DOTA-CCK-66 (DOTA-γ-glu-PEG3-Trp-(N-Me)Nle-Asp-1-Nal-NH2, PEG: polyethylene glycol) and DOTA-CCK-66.2 (DOTA-glu-PEG3-Trp-(N-Me)Nle-Asp-1-Nal-NH2), both derived from DOTA-MGS5 (DOTA-glu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-NH2), and clinically translate [68Ga]Ga-DOTA-CCK-66. Methods: 64Cu and 67Ga labeling of DOTA-CCK-66, DOTA-CCK-66.2, and DOTA-MGS5 was performed at 90°C within 15 min (1.0 M NaOAc buffer, pH 5.5, and 2.5 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffer, respectively). 177Lu labeling of these 3 compounds was performed at 90°C within 15 min (1.0 M NaOAc buffer, pH 5.5, 0.1 M sodium ascorbate). CCK-2R affinity of natGa/natCu/natLu-labeled DOTA-CCK-66, DOTA-CCK-66.2, and DOTA-MGS5 was examined on AR42J cells. The in vivo stability of 177Lu-labeled DOTA-CCK-66 and DOTA-MGS5 was examined at 30 min after injection in CB17-SCID mice. Biodistribution studies at 1 h ([67Ga]Ga-DOTA-CCK-66) and 24 h ([177Lu]Lu-DOTA-CCK-66/DOTA-MGS5) after injection were performed on AR42J tumor-bearing CB17-SCID mice. In a translation to the human setting, [68Ga]Ga-DOTA-CCK-66 was administered and whole-body PET/CT was acquired at 120 min after injection in 2 MTC patients. Results: Irrespective of the metal or radiometal used (copper, gallium, lutetium), high CCK-2R affinity (half-maximal inhibitory concentration, 3.6-6.0 nM) and favorable lipophilicity were determined. In vivo, increased numbers of intact peptide were found for [177Lu]Lu-DOTA-CCK-66 compared with [177Lu]Lu-DOTA-MGS5 in murine urine (23.7% ± 9.2% vs. 77.8% ± 2.3%). Overall tumor-to-background ratios were similar for both 177Lu-labeled analogs. [67Ga]Ga-DOTA-CCK-66 exhibited accumulation (percentage injected dose per gram) that was high in tumor (19.4 ± 3.5) and low in off-target areas (blood, 0.61 ± 0.07; liver, 0.31 ± 0.02; pancreas, 0.23 ± 0.07; stomach, 1.81 ± 0.19; kidney, 2.51 ± 0.49) at 1 h after injection. PET/CT examination in 2 MTC patients applying [68Ga]Ga-DOTA-CCK-66 confirmed multiple metastases. Conclusion: Because of the high in vivo stability and favorable overall preclinical performance of [nat/67Ga]Ga-/[nat/177Lu]Lu-DOTA-CCK-66, a proof-of-concept clinical investigation of [68Ga]Ga-DOTA-CCK-66 was completed. As several lesions could be identified and excellent biodistribution patterns were observed, further patient studies applying [68Ga]Ga- and [177Lu]Lu-DOTA-CCK-66 are warranted.
引用
- Günther T, Holzleitner N, Viering O, et al. Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [68Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer. J Nucl Med. 2024. PMID: 37945383. doi:10.2967/jnumed.123.266537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。